[HTML][HTML] Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection
The outbreak of 2019-novel coronavirus disease (COVID-19), caused by SARS-CoV-2,
started in late 2019; in a short time, it has spread rapidly all over the world. Although some …
started in late 2019; in a short time, it has spread rapidly all over the world. Although some …
Coronaviruses—drug discovery and therapeutic options
In humans, infections with the human coronavirus (HCoV) strains HCoV-229E, HCoV-OC43,
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …
HCoV-NL63 and HCoV-HKU1 usually result in mild, self-limiting upper respiratory tract …
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
VCC Cheng, SKP Lau, PCY Woo… - Clinical microbiology …, 2007 - Am Soc Microbiol
Before the emergence of severe acute respiratory syndrome (SARS) coronavirus (SARS-
CoV) in 2003, only 12 other animal or human coronaviruses were known. The discovery of …
CoV) in 2003, only 12 other animal or human coronaviruses were known. The discovery of …
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
Background First vaccines for prevention of Coronavirus disease 2019 (COVID‐19) are
becoming available but there is a huge and unmet need for specific forms of treatment. In …
becoming available but there is a huge and unmet need for specific forms of treatment. In …
Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies
J Dyall, R Gross, J Kindrachuk, RF Johnson… - Drugs, 2017 - Springer
No specific antivirals are currently available for two emerging infectious diseases, Middle
East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A …
East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A …
Nucleoside analogs and nucleoside precursors as drugs in the fight against SARS-CoV-2 and other coronaviruses
Coronaviruses (CoVs) are positive-sense RNA enveloped viruses, members of the family
Coronaviridae, that cause infections in a broad range of mammals including humans …
Coronaviridae, that cause infections in a broad range of mammals including humans …
Prospects for RNAi therapy of COVID-19
H Uludağ, K Parent, HM Aliabadi… - … in Bioengineering and …, 2020 - frontiersin.org
COVID-19 caused by the SARS-CoV-2 virus is a fast emerging disease with deadly
consequences. The pulmonary system and lungs in particular are most prone to damage …
consequences. The pulmonary system and lungs in particular are most prone to damage …
siRNA therapeutics against respiratory viral infections—What have we learned for potential COVID‐19 therapies?
Acute viral respiratory tract infections (AVRIs) are a major burden on human health and
global economy and amongst the top five causes of death worldwide resulting in an …
global economy and amongst the top five causes of death worldwide resulting in an …
Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation
Protein ISGylation is unique among ubiquitin-like conjugation systems in that the expression
and conjugation processes are induced by specific stimuli, mainly via the alpha/beta …
and conjugation processes are induced by specific stimuli, mainly via the alpha/beta …
[HTML][HTML] Development and application of ribonucleic acid therapy strategies against COVID-19
L Ning, M Liu, Y Gou, Y Yang, B He… - International Journal of …, 2022 - ncbi.nlm.nih.gov
Abstract The Coronavirus disease 2019 (COVID-19) pandemic is caused by the severe
acute respiratory syndrome 2 coronavirus (SARS-CoV-2), remaining a global health crisis …
acute respiratory syndrome 2 coronavirus (SARS-CoV-2), remaining a global health crisis …